These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10874917)

  • 1. [Rapaglinide: Novonorm, an alternative in type 2 diabetes].
    Bouhanick B; Barbosa SS
    Presse Med; 2000 May 27-Jun 3; 29(19):1059-61. PubMed ID: 10874917
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving management of type 2 diabetes mellitus: 4. Meglitinides.
    Quillen DM; Kuritzky L; Samraj GP
    Hosp Pract (1995); 1999 Dec; 34(13):38-40. PubMed ID: 10611897
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.
    Yin J; Deng H; Qin S; Tang W; Zeng L; Zhou B
    Diabetes Res Clin Pract; 2014 Sep; 105(3):e10-5. PubMed ID: 25005849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Repaglinide (NN-623)].
    Kaku K
    Nihon Rinsho; 1997 Nov; 55 Suppl():180-5. PubMed ID: 9434464
    [No Abstract]   [Full Text] [Related]  

  • 5. [Repaglinide].
    Quast U
    Dtsch Med Wochenschr; 2001 May; 126(19):559-60. PubMed ID: 11402913
    [No Abstract]   [Full Text] [Related]  

  • 6. The importance of rapid insulin secretion: revisited.
    Grodsky GM
    Diabetes Technol Ther; 1999; 1(3):259-60. PubMed ID: 11475271
    [No Abstract]   [Full Text] [Related]  

  • 7. Metformin/Repaglinide (PrandiMet) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Jun; 51(1313):41-3. PubMed ID: 19478691
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
    Khamaisi M
    Diabet Med; 2012 Sep; 29(9):1214-5. PubMed ID: 22414218
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.
    Tankova T; Koev D; Dakovska L; Kirilov G
    Diabetes Res Clin Pract; 2003 Jan; 59(1):43-9. PubMed ID: 12482641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 14. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
    Wolffenbuttel BH; Landgraf R
    Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin.
    Panelo A; Wing JR;
    Diabetes Care; 2005 Jul; 28(7):1789-90. PubMed ID: 15983336
    [No Abstract]   [Full Text] [Related]  

  • 19. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
    Kellerer M; Jakob S; Linn T; Haslbeck M
    MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
    [No Abstract]   [Full Text] [Related]  

  • 20. [Type 2 diabetes mellitus pathogenesis: new therapeutic managements?].
    Blicklé JF
    Rev Med Interne; 2003 Nov; 24(11):709-10. PubMed ID: 14604746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.